Considered for First-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients who have not received prior systemic therapy.
PBAC outcome
—
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have not received prior systemic therapy, with ECOG performance status of 2 or less.
Therapy area
Haematology
Line of therapy
First-line
Evidence base
Single-arm
Primary endpoint
OS
Key trials
Study 0114
Comparator
Treatment of Physician's Choice (TPC) consisting of AML-type, ALL-type, and lymphoma-type chemotherapy regimens
ICER note
ICER values redacted; document text ends before economic analysis section is presented